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To Fund or Not to Fund? Evaluating States’ Current Funding of IVF and PGD, the Impact 
of the Lack of Funding, and Why One Round of Coverage is Better than None 
 
I. Introduction 
The rapid evolution of both technology and modern medicine have presented the world 
with life-changing advancements.  And depending on who you ask, these advancements have 
been made for the better—or worse.  Additionally, when new technology presents citizens with 
medical options that were unimaginable years ago, the impact of utilizing, regulating, and 
funding such advancements is uncertain.  One of these technological advancements, specifically, 
is preimplantation genetic diagnosis (“PGD”).  Since its inception, this expensive procedure has 
raised many issues, both domestic and abroad, regarding access to the test, ethical uses of the 
test, and funding of the test. 
Preimplantation Genetic Diagnosis is a procedure whereby in vitro fertilized embryos can 
be tested to determine the presence or absence of certain genes or chromosomes.1  PGD testing 
requires in vitro fertilization (“IVF”), which substantially increases its cost.2  Currently, in the 
United States, there are only a handful of states that require insurance coverage for IVF, 
however, none of them require coverage for PGD.  This in turn, limits accessibility of the 
procedure to those of high socio-economic status.3  This increases the disparity of fertility 
opportunities.  In an effort to make IVF and PGD more accessible this article argues that each 
 
1 Thomas Lemke, Social dimensions of preimplantation genetic diagnosis: a literature review, 38 NEW GENETICS & 
SOC’Y 80, 80 (2018). 
2 Kathryn T. Drazba, Michele A. Kelley & Patricia E. Hershberger, A qualitative inquiry of the financial concerns of 
couples opting to use preimplantation genetic diagnosis to prevent the transmission of known genetic disorders, 23 
J. GENETIC COUNSELING 202, 202 (2013). 
3 Michelle Bayefsky & Bruce Jennings, REGULATING PREIMPLANTATION GENETIC DIAGNOSIS IN THE UNITED 
STATES: THE LIMITS OF UNLIMITED SELECTION 90 (2015). 
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state should require insurance coverage for at least one round of IVF and PGD; and provide such 
coverage regardless of the purpose for its use.  
Due to the lack of consistent funding for PGD combined with the ethnic prevalence of 
testable conditions, the United States’ current approach to funding PGD is discriminatory, 
creates disparities, and therefore states should require insurances provide for the treatment for all 
purposes. Section II of this article will discuss the purpose, process, prevalence, and cost of PGD 
in the United States.  Section III will discuss the current regulatory approaches implemented in 
foreign countries as well as those in the United States.  Section IV will highlight private funding 
and focus on the minimal insurers that have provided coverage for PGD.  And lastly, Section V 
will discuss the current and possible impacts of a lack of funding, and how those results may be 
mitigated. 
II. The Practice of PGD 
a. Purpose of PGD 
While assisted reproductive technologies (“ART”), such as PGD, have advanced rapidly 
within the past few decades, PGD tests cannot be used to identify certain traits such as eye color, 
hair color, height, intelligence, artistic ability, etc.4  Instead, PGD is limited to test for the 
presence, or absence, of certain genes and chromosomes.5  PGD patients that undergo IVF and 
PGD testing do so for many different purposes and reasons.  Some seek the procedures to ensure 
they have a child of a particular sex, while others undergo the procedures to give themselves the 
best chance in achieving a successful pregnancy or ensuring their child is not at risk for 
 
4 Jason Christopher Roberts, Customizing Conception: A Survey of Preimplantation Genetic Diagnosis and the 
Resulting Social, Ethical, and Legal Dilemmas, 2002 DUKE L. & TECH. REV. 12, 12 (2002). 
5 Arinze-Umobi Chinemelum Nelson, An Appraisal of the Ethics of Genetic Modification of Embryos and Its 
Implications on the Dignity of Human Species, 35 MED. & L. 509, 518 (2016). 
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developing certain genetic disorders.  Generally, the tests for PGD have been characterized by 
medical and nonmedical,6 or therapeutic and nontherapeutic.7   
The therapeutic tests are commonly used to detect single gene disorders such as cystic 
fibrosis, Tay-Sachs disease, and sickle cell anemia, as well as chromosomal abnormalities such 
as Down syndrome and Turner syndrome.8  The therapeutic use of PGD can test for numerous 
disorders, many of which are found predominately within certain ethnic groups.9 For example, 
beta thalassemia and sickle cell anemia are prevalent in African ethnicities. 10 Cystic fibrosis and 
Tay-Sachs disease are more prevalent in people of Jewish descent from Eastern Europe 
(Ashkenazi).11 And beta thalassemia is prevalent in Southeast Asian and Mediterranean 
ethnicities.12 The prevalence of certain disorders among ethnic groups indicates that people of 
those ethnicities are more likely to have the genetic disorder, and thus would highly benefit from 
accessible genetic testing.13 
The effect of these diseases on patients and their families highlights the importance of 
testing for therapeutic purposes. Infants born with cystic fibrosis in 2018 are predicted to live to 
be 47 years old.14 Although the life expectancy has increased over the years, living with cystic 
fibrosis requires daily treatments and may result in frequent hospitalizations and complications 
such as cystic fibrosis-related diabetes and depression.15 Additionally, children diagnosed with 
 
6 JA Robertson, Extending preimplantation genetic diagnosis: medical and non-medical uses, 29 J. MED. ETHICS 
213, 214 (2003). 
7 Jessica Knouse, Reconciling Liberty and Equality in the Debate over Preimplantation Genetic Diagnosis, 2013 
UTAH L. REV. 107, 121 (2013). 
8 Id.  





14 Understanding Changes in Life Expectancy, CYSTIC FIBROSIS FOUND., https://www.cff.org/Research/Researcher-
Resources/Patient-Registry/Understanding-Changes-in-Life-Expectancy/ (last visited Dec. 16, 2020). 
15 Id. 
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cystic fibrosis require a team of around six care takers, ranging from doctors to respiratory 
therapists, to properly treat the patient despite their inevitable early mortality.16 Unlike cystic 
fibrosis, Tay-Sachs disease is a progressive neurodegenerative disease.17 Despite the different 
pathophysiology of cystic fibrosis and Tay-Sachs disease, the emotional and financial impact on 
both the patient and family can be devastating. There is currently no cure for Tay-Sachs.18 
Treatment is available, however, which may include a number of prescription medications, 
various types of respiratory care, feeding tubes, and physical therapy.19  
Sex selection, on the other hand, is an example of a use for a nontherapeutic test.20  Sex 
selection, however, is difficult to define solely as a nontherapeutic test. It is important to note 
that although therapeutic and nontherapeutic tests seem distinct, one test may serve both 
therapeutic and nontherapeutic purposes.  For example, testing for sex serves the nontherapeutic 
purpose for parents seeking a child of a certain sex, yet testing for sex may also serve the 
therapeutic purpose of identifying X-linked diseases for others.21 
Another, technically medical, but highly controversial use of PGD is to create a “savior 
sibling.”22  Couples seek to create a savior sibling when they have a severely sick or dying child 
who needs a tissue or organ donation.23  This couple will undergo IVF, and doctors will then use 
PGD to pick an embryo that will be the near-perfect genetic organ or tissue match for the sick 
 
16 Parent and Guardian Guidance, CYSTIC FIBROSIS FOUND., https://www.cff.org/Life-With-CF/Caring-for-a-Child-
With-CF/Parent-and-Guardian-Guidance/ (last visited Dec. 16, 2020). 
17 Guillaume Sillon, Pierre Allard, Stella Drury, Jean-Baptiste Rivière & Isabelle De Bie, The incidence and carrier 
frequency of Tay-Sachs disease in the French-Canadian population of Quebec based on retrospective data from 24 
years, 1992-2015, 29 J. GENETIC COUNSELING 1173, 1173 (2020). 
18 Tay-Sachs disease, MAYO CLINIC (May 16, 2018), https://www.mayoclinic.org/diseases-conditions/tay-sachs-
disease/diagnosis-treatment/drc-20378193 (last visited Dec. 16, 2020). 
19 Id. 
20 Knouse, supra note 7 at 121.  
21 Id.  
22 Nelson, supra note 5 at 518. 
23 Marley McClean, Children’s anatomy v. children’s autonomy: a precarious balancing act with preimplantation 
genetic diagnosis and the creation of “savior siblings”, 43 PEPP. L. REV. 837, 839 (2016). 
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sibling.24  This use raises concern that the medical community will treat savior siblings as 
commodities, and thus lead to constant pressure [on the] savior siblings to donate whatever tissue 
was sought when creating the savior sibling in the first place.25  Creating a “savior sibling,” 
albeit controversial, is nonetheless a possibility with the use of PGD.  
PGD can also help detect known genetic diseases or chromosomal abnormalities that, if 
undetected, could result in a failed pregnancy.26  Therefore, good candidates for PGD include 
women who have had “repeated IVF failures, recurring miscarriages, or a history of genetically 
abnormal pregnancies,”27 as well as women over the age of 37.28  Women who are over the age 
of 37 are good candidates for PGD due to higher risk of abnormal embryo genetics with normal 
reproductive aging.29  The PGD patients, here, differ from those mentioned above because these 
patients want better chances of a successful pregnancy of a child—rather than a successful 
pregnancy of a child of a certain sex, or with a desired genetic make-up. 
b. Process of PGD 
The process of PGD can only be done during a cycle of IVF, thus an individual that 
wishes to test their embryo through PGD must also go through a cycle of IVF.30  So, taking into 
account both processes, the timeline for obtaining PGD includes: obtaining a full genetic work-
up (for both IVF and PGD), consultation to discuss genetic information and genetic history of 
 
24 Id. 
25 Id. at 846.  
26 Benefits & Risks of PGD/PGS (Preimplantation Genetic Testing), ADVANCED REPROD. MED. UNIV. COL., 
https://arm.coloradowomenshealth.com/services/ivf/pgd/risks (last visited Dec. 16, 2020). 
27 Preimplantation Genetic Diagnosis & Screening, N.Y.U. LANGONE MED. CTR., 
https://nyulangone.org/locations/fertility-center/preimplantation-genetic-testing (last visited Dec. 16, 2020). 
28 Preimplantation Genetic Testing (PGD), JOHNS HOPKINS MED., 
https://www.hopkinsmedicine.org/gynecology_obstetrics/specialty_areas/fertility-center/infertility-services/ART-
procedures/preimplantation-genetic-testing.html (last visited Dec. 16, 2020). 
29 Id.  
30 See Drazba, supra note 2, at 202.  
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both individuals who provide the sperm and egg, beginning IVF, and then finally testing the 
embryo once it has been fertilized, but before it is implanted into the woman’s uterus.31 
The prescreening and genetic work-up that precede IVF requires extensive testing of both 
gamete donors (collectively these individuals will be referred to as the “PGD patients”).  
Prescreening and the genetic work-up includes chromosomal/DNA testing, pedigree analysis, an 
assessment of risk, gynecology and andrology assessments, hormone tests, ovarian response test, 
semen analysis, as well as an evaluation confirming the chromosomal or genetic abnormality 
sought to be avoided.32 If needed, these tests may include analysis of family members’ genetic 
makeup.33  Once all of the preliminary screening and testing has been completed, the PGD 
patients may begin the first stages of the IVF procedure. 
One cycle of IFV can be broken down into several steps: “ovarian stimulation, egg 
retrieval, sperm retrieval, fertilization, and embryo transfer,” and will normally take two to three 
weeks.34  Throughout the course of this cycle, PGD patients may need different medications for 
particular issues, and will need to visit their doctor regularly.35  Once the cells have been 
fertilized, but before the embryo is transferred to the uterus, the PGD process can begin.36  
Regardless of what gene or chromosome for which the PGD patients are testing, PGD “involves 
the biopsy of a single or few cells” from the harvested embryo.37  Then, the collected cells will 
 
31 PREIMPLANTATION GENETIC DIAGNOSIS 151 (Joyce Harper ed., 2d ed. 2009). 
32 Id. 
33 Id.  
34 In vitro fertilization (IVF), MAYO CLINIC (Mar. 22, 2018), https://www.mayoclinic.org/tests-procedures/in-vitro-
fertilization/about/pac-20384716 (last visited Dec. 16, 2020). 
35 Id.  
36 Martine De Rycke & Veerle Berckmoes, Preimplantation Genetic Testing for Monogenic Disorders, 11 Genes 
871, 872 (2020). 
37 Id.  
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be tested for the presence or absence of the trait.  Lastly, the desired embryos are transferred to 
the uterus with the hope of having a viable pregnancy.38 
Retrieving the cells that will ultimately be tested, are extracted from the embryo through 
a biopsy procedure.  This biopsy procedure is consistent, regardless of what gene or chromosome 
is being tested.  Once the cells have been biopsied from the embryo, depending on the what the 
PGD patients wish to test for, the methods of testing may be either polymerase chain reaction 
(“PCR”) or fluorescence in situ hybridization (“FISH”).39  PCR is mainly used for autosomal 
single gene mutations, X-linked single gene mutations, gender selection, and HLA matching, 
while FISH may be used for aneuploidy screening, structural chromosomal abnormalities, and 
gender selection.40 
 Specifically, the PCR method of PGD testing can identify conditions mainly linked to 
genes, including Tay-Sachs disease, Sickle cell anemia, Duchenne muscular dystrophy, cystic 
fibrosis, hemochromatosis, as well as Huntington disease.41  Alternatively, the FISH method of 
PGD testing focuses more on evaluating the chromosomal makeup of a gene and can identify 
Down syndrome, Patau syndrome, Edwards syndrome (aka “Trisomy 18”), and Turner 
syndrome.42  FISH can also identify structural chromosomal abnormalities, meaning “part of an 
 
38 Genetic Testing, MAYO CLINIC (May 14, 2019), https://www.mayoclinic.org/tests-procedures/genetic-
testing/about/pac-20384827 (last visited Dec. 16, 2020) 
39 Practice Comm., Soc’y for Assisted Reprod. Tech. & Practice Comm., Am. Soc’y for Reprod. Med., 
Preimplantation Genetic Testing: A Practice Committee Opinion, 90 FERTILITY & STERILITY S136, S138 (2008). 
40 Id.  
41 Genetic All., D.C. Dep’t of Health, Understanding Genetics: A District of Columbia Guide for Patients and 
Health Professionals, (Feb. 17, 2010), 
https://www.ncbi.nlm.nih.gov/books/NBK132149/pdf/Bookshelf_NBK132149.pdf. 
42 Am. C. of Obstetricians and Gynecologists, Genetic Disorders, https://www.acog.org/womens-
health/faqs/genetic-disorders (last visited Nov. 4, 2020). 
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individual chromosome is missing, extra, switched to another chromosome, or turned upside 
down.”43 
Overall, the requirement of IVF to obtain PGD, and the processes by which are 
undertaken can last approximately three weeks.  Throughout this time, PGD patients are 
incurring medical expenses from costly medication and doctor’s visits, all in the hope of a 
successful cycle that yields the desired PGD results. 
c. Prevalence and Cost of PGD 
The extensive scholarly commentary on the issues of PGD and IVF would lead a reader 
to believe that these processes were extremely popular.  But in fact, only 1 to 2 percent of all 
U.S. births annually are via IVF.44  Further, of the 1 to 2 percentage that undergo IVF, only 
approximately 4 to 6 percent of those procedures elect to use PGD.45  Additionally, over 75 
percent of fertility clinics in the United States offer preimplantation genetic diagnosis.46  These 
low numbers may be attributable to the high costs associated with the procedures, paired with the 
lack of funding and insufficient insurance coverage.  
Generally, throughout the United States, PGD and IVF are extremely expensive 
procedures.  The combined cost, on average, of both the IVF and PGD procedures can range 
from $11,726 - $18,513 per cycle.47  An individual IVF cycle can range from $9,226-12,513, 
while PGD testing can cost an additional $2,500-6,000 per cycle.48 Undergoing IVF and PGD 
 
43 Genetic All., Understanding Genetics: A N.Y. – Mid-Atlantic Guide for Patients and Health Professionals, 
https://www.ncbi.nlm.nih.gov/books/NBK115563/pdf/Bookshelf_NBK115563.pdf (Jul. 8, 2009). 
44 IVF by the Numbers, PENN MED.: FERTILITY BLOG (March 14, 2018), 
https://www.pennmedicine.org/updates/blogs/fertility-blog/2018/march/ivf-by-the-
numbers#:~:text=The%20Centers%20for%20Disease%20Control,births%20annually%20are%20via%20IVF.  
45 William D. Winkelman, et. al, Public perspectives on the use of preimplantation genetic diagnosis, 32 J. ASSIST. 
REPROD. GENETICS 665, 665 (2005). 
46 Id.  
47 See Drazba, supra note 2, at 203.  
48 Id. 
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requires additional costs beyond the actual procedures as well.  Pre-cycle screening fees, fertility 
medications, and early pregnancy monitoring are all fees that will need to be considered in the 
calculation as well.49  These can add an additional expense of up to $20,000, on top of the cost of 
the PGD and IVF procedures.50  The persuasive presence of fertility clinics that provide PGD in 
the United States and low percentages of resulting pregnancies, suggests that the high cost of the 
procedures is a barrier to access the procedures. As discussed in Section III, infra, some states 
have enacted laws that mandate insurance coverage for IVF, although not PGD.  The laws are 
generally limited to individuals who have a family history of a genetic medical disease and if 
not, those who have shown infertility by one prescribed method or another.  Further, most of the 
states that have mandated insurance coverage for PGD and IVF, are silent on the issue of savior 
siblings. 
III. Regulatory Approaches 
a. Foreign Approaches 
PGD is largely outlawed around the globe, but there are a handful of countries, such as 
Italy, Switzerland, France, and the United Kingdom, that fund permitted uses of PGD.51  
Meaning, these countries fund PGD, but impose limitations as to who may use PGD and for what 
purposes.52  Until 2015, Italian Law no. 40 of February 19, 2004, permitted access to ART, such 
as PGD, only in cases of certified and incurable sterility or infertility of a couple.53  However, in 
2015, the Corte Constituzionale found that provision of Law no. 40 of February 19, 2004 to be 
unconstitutional and held it unreasonable to prohibit fertile couples who were carriers of genetic 
 
49 Leslie Evans, How Much Does PGD/PGT Cost? ORM GENOMICS, https://ormgenomics.com/2018/09/13/pgd-pgt-
cost/ (last visited Dec. 16, 2020). 
50 Id.  
51 See generally, Michelle J. Bayefsky, Comparative preimplantation genetic diagnosis policy in Europe and the 
USA and its implications for reproductive tourism, 3 REPROD. BIOMED. & SOC’Y ONLINE 41, 42-43 (2016).  
52 Id.  
53 Corte Cost., 14 maggio 2015, n. 96, Foro it. 2015, (It.). 
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diseases from having access to PGD.54  Today, Italy allows PGD for purposes aimed at 
protecting the health and development of the embryo itself, but has banned the use for sex 
selection purposes.55   
In 2017, Switzerland amended its reproductive laws allowing the use of assisted 
reproductive techniques, such as PGD, by infertile couples and couples that pose an unavoidable 
risk of transferring a serious disease to their offspring.56 Switzerland also increased the amount 
of embryos that may be harvested in a single cycle from 3 embryos — when the article was 
approved — to now allowing 12 embryos per cycle.57  In France, PGD used for HLA matching is 
generally permitted, while any other use of PGD must be approved by a Centre Pluridisciplinaire 
de Diagnostic Prenatal and is limited to selecting against a serious, incurable diseases.58  
Similarly, in the United Kingdom, the Human Fertilization and Embryology Acts of 1990 and 
2008 authorized the Human Fertilization and Embryology Authority (“HEFA”) to regulate 
ART.59  This regulatory body regulated precisely the conditions for which PGD can be used and 
has concluded that PGD can be used to select against serious medical conditions or to select for 
an HLA match for a sick relative.60 
The few foreign countries that permit PGD vary slightly in their regulations, but still 
impose strict limitations on who may access PGD and on what terms. The approaches taken by 
Italy, Switzerland, France, and the United Kingdom differ significantly from the United States’ 




55 Bavefsky, supra note 50 at 42.  
56 BUNDESVERFASSUNG [BV] [CONSTITUTION] Dec. 18, 1998, SR 810.11, art. 5 (Switz.). 
57 BUNDESVERFASSUNG [BV] [CONSTITUTION] Dec. 18, 1998, SR 810.11, art. 17 (Switz.). 
58 Bavefsky, supra note 50 at 43.  
59 Human Fertilisation and Embryology Act, 1990, c. 37, §§ 5, 8 (Eng). 
60 Bavefsky, supra note 50 at 42-43. 
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b. United States’ Approach  
In contrast to the foreign government regulation discussed above, the United States 
government has maintained a “hands-off” approach when it comes to PGD—there are currently 
no federal regulations or funding for the procedure.  It further seems unlikely that the United 
States would adopt any of the approaches taken by Italy, Switzerland, France, or the United 
Kingdom, considering three, interrelated features of the United States: the lack of government 
sponsored healthcare, the independence of medical professionals, and the controversy 
surrounding embryos.61  
First, Italy, France, and the United Kingdom for the most part, have government funded 
healthcare.62  Because the government funds the healthcare, they can also determine what, and 
what not, to cover.  To best demonstrate how this would not be possible in the United States, a 
few examples are illustrative.  In France, “the government-sponsored insurance funds up to four 
IVF cycles, but only for heterosexual couples.”63  In the United Kingdom, the number of cycles 
funded by the government depends on the woman’s age—women between the ages of 23 and 39 
can receive up to three cycles, while women between the ages of 40 and 42 are limited to one 
cycle.64  These approaches would not be sustainable in the United States.  Although government 
funding would be helpful, it would come at the cost of sacrificing reproductive rights and 
limiting the autonomy Americans have when exercising their right to procreate and right to 
parent.   
Second, absent government funding and regulation, assisted reproduction “is directed by 
market forces,” which allows “physicians to offer the services they want to provide and charge 
 
61 See generally id. at 43-45  
62 Id. at 44.  
63 Id.  
64 Bavefsky, supra note 51 at 43-45.  
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the fees they deem appropriate.”65  As a result, many physicians have come to value their relative 
independence, including their financial independence, and therefore have a strong motivation to 
resist government regulation.66  So, insisting that the United States fund PGD would lead to 
undesirable regulation of both consumers and healthcare providers.  
Lastly, the United States government distanced themselves from issues surrounding 
embryonic politics when it enacted the 1995 Dickey-Wicker Amendment—prohibiting the use of 
federal funds for research that involves the creation or destruction of human embryos.67  PGD 
escalates the controversy due to the fact that the practice often involves the destruction of excess 
embryos, and in the context of PGD, the discarded embryos contain an undesired genetic 
feature.68  In addition to the close relationship of the destruction of embryos to the fierce 
domestic abortion debate, it seems nonsensical to suggest funding of PGD by the United States 
government.69 
While government funding of PGD works in some foreign countries, their approaches 
would ultimately not translate into the United States’ setting.  As illustrated by Italy, France, and 
the United Kingdom, with funding comes invasive regulations; and insisting the United States 
government fund PGD in the States would give them leeway to begin regulating this assisted 
reproductive technology.  Additionally, considering the independence of medical professionals 
and the issues surrounding embryo politics, a push for PGD funding by the United States 
government seems unrealistic.  
 
65 Id.  
66 Id.  
67 Balanced Budget Downpayment Act, I, Pub. L. No. 104-99, 110 Stat. 34 (1996). 
68 Bavefsky, supra note 51 at 44-45.  
69 Bavefsky, supra note 51 at 45.  
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Like the federal government, the States have generally kept hands-off in regulating PGD.  
However, there are a handful of states that have mandated coverage for IVF.70  This may seem 
like a step in the right direction; however, the states71 that mandate coverage for IVF have 
required the bare minimum coverage, subject to arbitrary qualifications.72  Other states, such as 
California,73 Louisiana,74 and New York,75 have done quite the opposite by explicitly excluding 
coverage for the IVF. 
Massachusetts, although mandating coverage of IVF, does so with some of the least 
restrictive means to obtain coverage.  Massachusetts requires coverage of diagnosis and 
treatment of infertility.76  “Infertility” is defined as the “condition of an individual who is unable 
to conceive or produce conception during a period of one year if the female is age 35 or younger 
or during a period of six months if the female is over the age of 35;” the statute continues on to 
note the time periods commence “of the time she attempted to conceive prior to achieving that 
pregnancy.”77  Massachusetts also includes a clause prohibiting “exclusions, limitations or other 
restrictions on coverage for fertility-related drugs that are different from those imposed on any 
other prescription drugs.”78  So, to be eligible for required coverage in Massachusetts, PGD 
patients must provide proof of only one year—or six months—depending on age, of infertility.  
And the statute further provides protection of coverage for any fertility-related drugs required for 
the procedures. 
 
70 State Law Related to Insurance Coverage for Infertility Treatment, NAT’L CONF. OF ST. LEGISLATURES (Jun. 12, 
2019), https://www.ncsl.org/research/health/insurance-coverage-for-infertility-laws.aspx.  
71 Delaware, Arkansas, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, and New Jersey.  Id.  
72 Id.  
73 CAL. INS. CODE § 10119.6(a) (Deering 2020); CAL. HEALTH & SAF. CODE § 1374.55(a) (Deering 2020). 
74 LA. STAT. ANN. § 22:1036(a)(1)(b) (2020). 
75 N.Y. INS. LAW § 3221 (Consol. 2020). (law explicitly excludes coverage, subject to limited circumstances) 
76 MASS. ANN. LAWS CH. 176G, § 4 (LexisNexis 2020) 
77 MASS. ANN. LAWS CH. 175, § 47H (LexisNexis 2020); MASS. ANN. LAWS CH. 176A, § 8K (LexisNexis 2020); 
MASS. ANN. LAWS CH. 176B, § 4J (LexisNexis 2020). 
78 211. 37. MASS. CODE REGS. 37.06. (LexisNexis 2020). 
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Opposite from Massachusetts’s least restrictive regulations for IVF and PGD is Hawaii.  
Within Hawaii’s statutes, there is a section dedicated to in vitro fertilization procedure 
coverage.79  This section defines the five requirements that, if satisfied, would trigger coverage, 
as well as limitations in quantity and scope.80  This statute limits coverage to a one-time only 
benefit for all outpatient expenses arising from in vitro fertilization procedures.81  The 
requirements that must be met include: the patient is the insured, the sperm that fertilizes the 
eggs must be the patient’s spouse’s sperm, the patient and patient’s spouse must have a history of 
infertility of at least five years’ duration (or infertility is associated with one or more of four 
listed medical conditions), other covered infertility treatments have proven unsuccessful for the 
patient, and the in vitro fertilization procedures are performed at medical facilities that conform 
to the American College of Obstetricians and Gynecologists (“ACOG”) guidelines for in vitro 
fertilization clinics or to the American Society for Reproductive Medicine minimal standards for 
programs of in vitro fertilization.82  
In contrast to Massachusetts, Hawaii mandates coverage for only one cycle of IVF 
(limited to the outpatient expenses), requires proof of five consecutive years of infertility, 
requires the patient’s eggs are fertilized by the patient’s spouse’s sperm, and requires proof that 
all other covered infertility treatments have failed.  The stark contrast between the Massachusetts 
and Hawaii statutes illustrates the inconsistent access to coverage among the states. 
While some of the limitations may be attributable to the differences in culture across the 
United States, others seem to be selected and applied arbitrarily.  For example, PGD patients 
seeking, at least, coverage of IVF in Hawaii must prove, absent four specified medical 
 
79 HAW. REV. STAT. ANN. § 431:10A-116.5 (LexisNexis 2020). 
80 Id.  
81 Id.  
82 Id.  
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conditions, infertility for a duration of five years.83  Meanwhile, PGD patients in Massachusetts 
only have to prove infertility of, at most, one year to be eligible for coverage.84  There seems to 
be some support for Massachusetts’s one-years duration found in the Centers for Disease Control 
and Prevention’s definition of “infertility” as “not being able to get pregnant (conceive) after one 
year (or longer) of unprotected sex.”85  While this definition seems to provide Massachusetts 
with slight justification, despite the lowered six-month duration of infertility, it does nothing to 
justify Hawaii’s requirement of five years’ duration.  This amount of time, specifically, could be 
detrimental to a woman’s goal of achieving a successful pregnancy, especially if she is over the 
age of 37. 
In addition to Massachusetts and Hawaii, eleven other states also require insurance to 
cover IVF. These states include Arkansas,86 Colorado,87 Connecticut,88 Delaware,89 Illinois,90 
Maryland,91 New Hampshire,92 New Jersey,93 New York,94 Rhode Island,95 and Utah.96 As 
medical technologies continue to evolve, the number of women in the United States utilizing 
 
83 HAW. REV. STAT. ANN. § 431:10A-116.5 (LexisNexis 2020). 
84 MASS. ANN. LAWS CH. 175, § 47H (LexisNexis 2020); MASS. ANN. LAWS CH. 176A, § 8K (LexisNexis 2020); 
MASS. ANN. LAWS CH. 176B, § 4J (LexisNexis 2020). 
85 Infertility FAQs, CTR. FOR DISEASE CONTROL & PREVENTION, 
https://www.cdc.gov/reproductivehealth/infertility/index.htm (last reviewed Jan. 16, 2019).  
86 ARK. CODE. ANN. § 23-85-137 (2011); ARK. CODE. ANN. § 23-86-118 (1987). 
87 COLO. REV. STAT. § 10-16-104(23) (2020). (applicable to health benefits issued or renewed in Colorado on or after 
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medical technologies to overcome infertility also increases.97 Insurance coverage, however, is 
slow to keep up with the need for treatments due to the fact that infertility treatments have been 
deemed not to be a medical necessity.98 As more states have mandated such coverage, opponents 
argue that these mandates may do more harm than good by forcing insurers to offer benefits for 
services that people might not want.99 This, they argue, would lead to harmful side effects, such 
as increased costs, while not adequately providing coverage for everyone. These thirteen states 
are the firsts to mandate coverage of IVF, notwithstanding the fact they have done so reluctantly. 
Their limitations and restrictions in mandating IVF coverage are reflective of the United States’ 
hesitant approach regarding PGD.       
IV. Private Funding and Focus on the Insurances 
Despite the United States keeping a hands-off approach towards PGD, there are two 
major, private health insurance providers that include coverage for PGD—Aetna (“Aetna”) and 
United Healthcare (“United”).100  Aetna and United took it upon themselves to include the 
coverage for PGD, however, the terms impose great restrictions and limitations for available 
coverage.  
Aetna’s coverage of IVF and PGD is severely limited.  As an initial matter, “the IVF 
procedure . . . is covered only for persons with ART benefits who meet medical necessity criteria 
for IVF.”101  PGD is covered only when “medically necessary” to identify single gene mutations 
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or X-related conditions.102  PGD is further limited by requiring that the “genetic disease [to be 
detected] is associated with clinically significant morbidity or disability.”103  Aetna also notes in 
their PGD policy, that the use of PGD to determine the human leukocyte antigen (HLA) — to 
create a “savior sibling”— is considered “experimental and investigational”, and is therefore not 
covered.104  Essentially, Aetna requires consumers to purchase their ART coverage plan, which  
may cover IVF, and even if it does, the coverage of PGD is limited to the detection of genetic 
diseases that result in significant risk of suffering from a disease or disability.  What is 
considered a disease that would result in significant risk of suffering from a disease or disability 
is unspecified and unclear.  Aetna further explicitly excludes PGD for testing of HLA.  So, if a 
couple wishes to undergo IVF and PGD to create a savior sibling, coverage for that purpose will 
not be provided, regardless of whether the couple has purchased the ART coverage plan. 
Similar to Aetna, United’s coverage for PGD delineates when the PGD procedure is 
medically necessary for the following, qualifying risks: 
the embryo is at increased risk of a recognized inherited disorder with both of the following: 
 The increased risk of a recognized inherited disorder is due to one of the following: 
o The parents are carriers of an autosomal recessive disease 
o At least one parent is a carrier of an autosomal dominant, sex-linked, or 
mitochondrial condition 
o At least one parent is a carrier of a balanced structural chromosome 
rearrangement 
 The medical condition being prevented must result in Significant Health Problems or 
Severe Disability and be caused by a single gene (PGT-M) or structural changes of a 
parents’ chromosome (PGT-SR).105  
 
 
102 Id.  
103 Id.  
104 Id.  




This is similar to Aetna’s coverage in limiting the uses, as well as requiring that the condition 
result in health problems or disability.  However, under United’s plan, human leukocyte antigen 
(HLA) typing on an embryo in order for the future child to provide bone marrow or blood to treat 
an affected sibling is considered a medical necessity.106  This provision does allow PGD to create 
a “savior sibling,” however, the policy limits the type of tissue the savior sibling can donate by 
permitting the donation of only bone marrow and blood.  This clause is far more permissive than 
Aetna’s ban on providing coverage to create a savior sibling. However, it’s still restrictive. In 
one of the more extreme cases, an individual may seek to create a savior sibling for the purpose 
of providing an organ, such as a kidney, to a sick family member. This case would not be 
covered under United’s plan because it exceeds the scope of permissible donative tissues.107 
The policies provided by Aetna and United seem fairly permissive on their face.  
However, a closer look into both policies shows the strict requirements and limitations placed on 
what tests will actually be covered.  These insurers provide coverage to single genetic disorders 
(subject to other qualifications), only one provides coverage to the limited use of PGD to 
produce a “savior sibling,” and neither cover testing for sex selection.  It is a step in the right 
direction for PGD coverage to be listed on an insurance plan, however, the vast limitations and 
qualifications effectively deem these plans useless in trying to provide equal access to the 
testing. 
V. Impact of Lack of Funding 
The lack of state mandated insurance coverage for PGD and IVF has resulted in unequal 
access to both procedures.  ART, in general, “is deeply divided on race and class lines given the 
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expense of accessing ART services.  This inequality of access is furthered by the high cost, and 
lack of insurance coverage for these services.”108  This inequality is further perpetrated by the 
fact that a majority of states limit coverage of IVF,109 which is the most expensive fertility 
treatment, 110 and provide no guidance on PGD coverage.111 
Looking more broadly at restricted access to ART, minority women are less likely to 
access ART due to cost, education, and cultural beliefs.112  Further, in narrowing the scope to 
evaluate the diseases detectable by PGD, there are multiple diseases that are more common 
amongst certain ethnic groups that can be discovered through PGD.  For example, Edwards 
syndrome (aka “Trisomy 18”) has a much higher occurrence in non-Hispanic American 
Indian/Alaskan Natives.113  Sickle Cell Disease (“SCD”) occurs among about 1 out of every 365 
Black or African American births versus 1 out of every 16,300 Hispanic-American births.114 
Tay-Sachs disease, although rare in the general population, is more common in people of 
Ashkenazi (eastern and central European) Jewish heritage than in those with other 
backgrounds.115 And beta thalassemia is prevalent in Southeast Asian and Mediterranean 
ethnicities. The fact that these genetic disorders are “found predominately within certain ethnic 
groups [sic] raises the degree of suspicion that a genetic disorder is present and may mandate 
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genetic testing if available.”116 Further, in the United States, “it is the racial minorities, 
particularly Black, Latino, and immigrant communities, that bear the adverse consequences of ill 
health due to poverty, lack of insurance, and, in turn, lack of access to health serviced and 
technologies.”117 This supports the push for equal access to PGD testing through state mandated 
coverage. 
Even in the several states that do provide coverage for IVF through state law mandates,118 
there is not equal access to the procedure for everyone.119  
Mandates do not apply to those who obtain health coverage through 
governmental programs (such as Medicaid), and are uninsured, or obtain health 
coverage from self-insured employers.  As a result, even in mandates states, 
infertility care has been accessed disproportionately by non-Hispanic white 
women with higher educational training and socioeconomic status.120 
 
 This point illustrates that, although it’s not likely to happen anytime soon, the United States 
government should continue to consider the lack of equal access to IVF and PGD and the 
possibility of regulating the procedure. As new technologies develop, the lack of access to these 
technologies may further inequalities of illness and worsen the burden of disease for particular 
communities.121 Although state mandated insurance coverage for PGD may not provide every 
single person with access to PGD, the need to start moving toward better accessibility and 
closing the disparate gap is a pressing matter.  
Opponents of the issues of equality — ensuring that everyone has equal access to the IVF 
and PGD — argue that perhaps “any proposal to fund PGD use to screen out genetic illness or 
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chromosomal abnormalities impacts the disabled.”122  When PGD patients elect to undergo the 
test, there is an understanding that a possibility exists where an embryo may hold an “undesirable 
trait,” which may result in its disposal.  In doing so, “efforts to deselect embryos for disabilities 
can be seen as a failure to understand the value of the lives of the disabled.”123  It is further 
argued that “funding for therapeutic PGD may create pressure to deselect embryos because doing 
so is what the government and society believe is right.”124  The idea behind this argument is that 
because the test is funded by the government, there is a pressure to conform to what the 
government and society deem is “right” or “correct.”125  And as such pressure continues and 
grows, society will feel the need to conform to and receive the test to ensure they do not have a 
“disabled child.”126 Its further argued that this societal pressure would in turn reduce the number 
of disabled people, while the social stigma of being different is likely to increase.127 
This argument, however, is based on two very important premises: 1) that the PGD 
testing would be funded directly by the government; and 2) that individuals who wish to have a 
child with traits that others would consider to be undesirable would not utilize PGD.128  State 
mandates that require insurance companies to cover at least one round of PGD and IVF are not 
based on government funding.129  Additionally, there is no requirement that all insured PGD 
patients go through the process of IVF or PGD.  Couples insured in the states that have mandated 
coverage will not be prevented from conceiving a child naturally, or by any other fertility 
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treatment.  The state mandate coverage simply is in place for those who wish to utilize PGD and 
IVF, who would otherwise not have the means or option to do so.  
This approach eliminates the idea that the government, through funding, will be able to 
influence what is “correct” or “right” in our society.  Further, individuals who are seeking a 
certain trait and those that are seeking to avoid that same certain trait would both have equal 
access to undergo PGD to obtain their respective desired results. Individuals who seek to have a 
child with a certain trait that others may deem “undesirable,” would not prohibit the individual 
from otherwise undergoing PGD to ensure the child had that specific trait.   
Moreover, the potentially negative social stigma attributable to the use of PGD would 
require widespread and persuasive use of PGD to affect that result. A study published in 2019 
sought to examine the extent to which health plan expenditures for infertility services differed by 
whether women resided in states with mandates requiring coverage of such services and by 
whether coverage was provided through a self-insured plan subject to state mandates versus fully 
insured health plans. subject only to federal regulations.130 The study included a little over six 
million women, 19-45 years of age.131 The study observed the women, continuously enrolled in 
different insurance plans for 2011, and tracked whether the women sought certain fertility 
treatments including IVF, intrauterine insemination, or ovulation-inducing medications.132 Of the 
6,006,017 women enrolled in the study, only 9,199 women — or 0.15% — had one or more IVF 
claims.133 And less than 65% of those 9,199 women lived in a state with an infertility insurance 
mandate.134 This study indicates that even where fertility treatments are accessible to many 
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women, a majority most likely will not receive the treatment for one reason or another. These 
numbers, in turn, are not large enough to persuasively suggest a negative social stigma arising 
from accessible IVF and PGD testing.   
There has also been a slippery slope argument that has been made against providing 
insurance coverage for PGD and IVF.  There is a concern that once PGD and IVF have become 
so prevalent in society, or society begins to feel the pressure of electing to undergo PGD, 
insurance providers will eventually stop providing coverage for conditions that are 
“preventable.” Meaning, those conditions that could be detected through PGD, should be 
detected through PGD. Furthermore, there is a fear that once insurance coverage becomes widely 
accessible, insurance providers will begin to tack on extra costs and fees for individuals who 
choose to procreate without using PGD.135  Opposite from the social stigma argument, the fear 
that insurance providers could eventually punish carriers for not utilizing PGD and IVF doesn’t 
rely on the number of individuals who actually undergo the procedures. When insurance 
companies provide coverage for certain treatments, there is the possibility that the cost of the 
coverage plan will increase. To offset that increase in costs caused by providing coverage for 
PGD and IVF, insurance companies could charge carriers who do not utilize the service. 
However, this would be a far overreach by the insurance companies due to the invasive nature 
and requirements of the IVF and PGD procedures. 
Considering the unworkable foreign approaches to funding PGD and the United States’ 
unwillingness to become involved in any domestic approach, the states136 seem to be in the best 
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position to mandate insurance coverage of at least one cycle of IVF and PGD — regardless of 
the purpose or reason for utilizing the procedures. The states thus far have placed arbitrary 
requirements on proving infertility, which would only then trigger coverage for IVF.  These 
arbitrary requirements include the length of time one must be unable to have a child to be 
deemed “infertile,” and how many failed cycles of IVF one must endure before coverage 
activates.  
The coverage suggested in this Article requires at least one cycle of PGD and IVF, even 
if it is the first attempt for a couple to become pregnant, and regardless of what gene or 
chromosome the patients are seeking to test.  After, the states may regulate subsequent cycles as 
they please, subject to constitutional restraints.  Mandating at least one covered cycle of PGD 
and IVF, rather than mandating blanket coverage, will provide equal access to the procedures 
regardless of the reason of testing, while mitigating any stigmatizing effect on individuals with 
conditions deemed undesirable that could be detected through PGD. 
The issues with the current state mandates are that they are scarce and extremely 
restrictive — only a few states have them, and only a few uses of IVF are covered.  Additionally, 
the statutes leave out any possibility of coverage in the event PGD patients want to produce a 
“savior sibling,” so, PGD patients who want HLA testing do not even have a chance for coverage 
under the current mandates.  The statutes limit the uses to particular genetic disorders, rather than 
all, and require other arbitrary limitations.  In doing so, the states have gone into unnecessary 
hair-splitting detail with their legislation. This ultimately indicates the state’s approval for some 
uses, while showing disapproval for other uses.  However, it is not for the state to decide what 
the good uses are for PGD versus the bad uses and what tests should be allowed versus those that 
should not be allowed.  
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VI. Conclusion 
In conclusion, states should require insurance providers to cover at least one cycle of IVF 
with PGD.  Further, the coverage should be provided absent a showing of infertility or familial 
history of genetic disorders.  The few states that do require health insurers to cover these 
procedures, and the existing coverage by Aetna and United, limit the access to coverage with 
arbitrary bounds. 
This unequal access to ART, generally, has a disparate impact against various minority 
groups.  Further, because PGD can detect the presence of specific diseases that are more 
common among certain ethnic groups, it would be prejudicial to restrict access to the testing.  
Where individuals have access to PGD and IVF, patients will have the opportunity to potentially 
rid their child of the common disease.  
Government involvement in regulating PGD, as it stands today does not seem like a 
feasible option, without impeding a family’s right to reproduce and family plan.  Regulatory 
framework abroad cannot translate to practice in the United States, as the foreign countries 
placed heavy restrictions on, what in the United States are, developed fundamental rights.  
Regulations coming from the federal government and delineating when coverage for PGD is 
acceptable would eventually lead to a separation of “acceptable” uses and “nonacceptable” 
uses—determined by the government.  With the growing number of uses for PGD, not calling for 
blanket coverage for at least one cycle of treatment would compartmentalize the ethical status of 
testing, and at the same time prevent a family to have a child they want to have, as in the case of 
the savior sibling.  While equal access to PGD testing is important, it cannot be limited to those 
families with existing genetic disorders, it must be accessible for at least one cycle—regardless 
of purpose, or not at all. 
